{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:12:51Z","timestamp":1765887171143,"version":"3.37.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T00:00:00Z","timestamp":1245801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00702-009-0253-6","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T18:23:48Z","timestamp":1251224628000},"page":"1079-1086","source":"Crossref","is-referenced-by-count":22,"title":["Neuroprotective effects of probenecid in a transgenic animal model of Huntington\u2019s disease"],"prefix":"10.1007","volume":"116","author":[{"given":"Eniko","family":"Vamos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Voros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denes","family":"Zadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Vecsei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Klivenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,24]]},"reference":[{"key":"253_CR1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.nurt.2008.01.008","volume":"5","author":"OR Adam","year":"2008","unstructured":"Adam OR, Jankovic J (2008) Symptomatic treatment of Huntington disease. Neurotherapeutics 5:181\u2013197","journal-title":"Neurotherapeutics"},{"key":"253_CR2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","volume":"55","author":"MF Beal","year":"1990","unstructured":"Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynurenine pathway measurements in Huntington\u2019s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327\u20131339","journal-title":"J Neurochem"},{"key":"253_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","volume":"108","author":"MF Beal","year":"1992","unstructured":"Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED (1992) Kynurenic acid concentrations are reduced in Huntington\u2019s disease cerebral cortex. J Neurol Sci 108:80\u201387","journal-title":"J Neurol Sci"},{"key":"253_CR4","first-page":"9","volume":"12","author":"DW Choi","year":"1988","unstructured":"Choi DW (1988) Alzheimer\u2019s disease and dementia. Med Sect Proc 12:9\u2013155","journal-title":"Med Sect Proc"},{"key":"253_CR5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650\u20131654","journal-title":"Science"},{"key":"253_CR6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1471-4159.1989.tb02552.x","volume":"52","author":"JH Connick","year":"1989","unstructured":"Connick JH, Carla V, Moroni F, Stone TW (1989) Increase in kynurenic acid in Huntington\u2019s disease motor cortex. J Neurochem 52:985\u2013987","journal-title":"J Neurochem"},{"key":"253_CR8","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990\u20131993","journal-title":"Science"},{"key":"253_CR9","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-004-0201-4","volume":"111","author":"G Gardian","year":"2004","unstructured":"Gardian G, Vecsei L (2004) Huntington\u2019s disease: pathomechanism and therapeutic perspectives. J Neural Transm 111:1485\u20131494","journal-title":"J Neural Transm"},{"key":"253_CR10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/jpet.102.035014","volume":"302","author":"PM Gerk","year":"2002","unstructured":"Gerk PM, Vore M (2002) Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 302:407\u2013415","journal-title":"J Pharmacol Exp Ther"},{"key":"253_CR11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ (1999) Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci 19:2522\u20132534","journal-title":"J Neurosci"},{"key":"253_CR12","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","volume":"21","author":"C Hilmas","year":"2001","unstructured":"Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463\u20137473","journal-title":"J Neurosci"},{"key":"253_CR13","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1096\/fasebj.3.14.2574119","volume":"3","author":"PF Juranka","year":"1989","unstructured":"Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583\u20132592","journal-title":"FASEB J"},{"key":"253_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2007.03.004","volume":"258","author":"A Lazarowski","year":"2007","unstructured":"Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A (2007) Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 258:84\u201392","journal-title":"J Neurol Sci"},{"key":"253_CR15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1023\/B:PHAM.0000036905.82914.8e","volume":"21","author":"G Lee","year":"2004","unstructured":"Lee G, Bendayan R (2004) Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 21:1313\u20131330","journal-title":"Pharm Res"},{"key":"253_CR16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/mol.107.039594","volume":"73","author":"ZP Lin","year":"2008","unstructured":"Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, Sartorelli AC (2008) Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol 73:243\u2013251","journal-title":"Mol Pharmacol"},{"key":"253_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506","journal-title":"Cell"},{"key":"253_CR18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0306-4522(96)00655-0","volume":"78","author":"AF Miranda","year":"1997","unstructured":"Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K (1997) Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78:967\u2013975","journal-title":"Neuroscience"},{"key":"253_CR19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1471-4159.1988.tb04852.x","volume":"51","author":"F Moroni","year":"1988","unstructured":"Moroni F, Russi P, Lombardi G, Beni M, Carla V (1988) Presence of kynurenic acid in the mammalian brain. J Neurochem 51:177\u2013180","journal-title":"J Neurochem"},{"key":"253_CR20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.33549\/physiolres.931049","volume":"56","author":"V Perez-De La Cruz","year":"2007","unstructured":"Perez-De La Cruz V, Santamaria A (2007) Integrative hypothesis for Huntington\u2019s disease: a brief review of experimental evidence. Physiol Res 56:513\u2013526","journal-title":"Physiol Res"},{"key":"253_CR21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","volume":"306","author":"H Potschka","year":"2003","unstructured":"Potschka H, Fedrowitz M, Loscher W (2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306:124\u2013131","journal-title":"J Pharmacol Exp Ther"},{"key":"253_CR22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2006.03.051","volume":"402","author":"C Prescott","year":"2006","unstructured":"Prescott C, Weeks AM, Staley KJ, Partin KM (2006) Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402:108\u2013112","journal-title":"Neurosci Lett"},{"key":"253_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/156802609787521544","volume":"9","author":"S Rapposelli","year":"2009","unstructured":"Rapposelli S, Digiacomo M, Balsamo A (2009) P-gp transporter and its role in neurodegenerative diseases. Curr Top Med Chem 9:209\u2013217","journal-title":"Curr Top Med Chem"},{"doi-asserted-by":"crossref","unstructured":"Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 100:9244\u20139249","key":"253_CR36","DOI":"10.1073\/pnas.1033060100"},{"key":"253_CR24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0022-510X(92)90251-F","volume":"113","author":"GP Reynolds","year":"1992","unstructured":"Reynolds GP, Pearson SJ (1992) Neurochemical abnormalities in Huntington\u2019s disease: neurotoxic mechanisms and neurotransmitter changes. J Neurol Sci 113:230\u2013233","journal-title":"J Neurol Sci"},{"key":"253_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ana.410190202","volume":"19","author":"SM Rothman","year":"1986","unstructured":"Rothman SM, Olney JW (1986) Glutamate and the pathophysiology of hypoxic\u2013ischemic brain damage. Ann Neurol 19:105\u2013111","journal-title":"Ann Neurol"},{"key":"253_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0028-3908(95)00145-X","volume":"35","author":"A Santamaria","year":"1996","unstructured":"Santamaria A, Rios C, Solis-Hernandez F, Ordaz-Moreno J, Gonzalez-Reynoso L, Altagracia M, Kravzov J (1996) Systemic dl-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology 35:23\u201328","journal-title":"Neuropharmacology"},{"key":"253_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","volume":"197","author":"MT Sapko","year":"2006","unstructured":"Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington\u2019s disease. Exp Neurol 197:31\u201340","journal-title":"Exp Neurol"},{"key":"253_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/0470846356.ch3","volume":"243","author":"GL Scheffer","year":"2002","unstructured":"Scheffer GL, Scheper RJ (2002) Drug resistance molecules: lessons from oncology. Novartis Found Symp 243:19\u201331","journal-title":"Novartis Found Symp"},{"key":"253_CR29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397\u2013407","journal-title":"Hum Mol Genet"},{"key":"253_CR30","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410240417","volume":"24","author":"R Schwarcz","year":"1988","unstructured":"Schwarcz R, Tamminga CA, Kurlan R, Shoulson I (1988) Cerebrospinal fluid levels of quinolinic acid in Huntington\u2019s disease and schizophrenia. Ann Neurol 24:580\u2013582","journal-title":"Ann Neurol"},{"key":"253_CR7","author":"WR Silverman","year":"2009","unstructured":"Silverman WR, De Rivero VJP, Locovei S, Qiu F, Carlsson SK, Scemes E, Keane RW, Dahl G (2009) The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem. doi: 10.1074\/jbc.M109.004804","journal-title":"J Biol Chem"},{"key":"253_CR31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1006\/nbdi.2001.0438","volume":"8","author":"DL Smith","year":"2001","unstructured":"Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP (2001) Inhibition of polyglutamine aggregation in R6\/2 HD brain slices-complex dose-response profiles. Neurobiol Dis 8:1017\u20131026","journal-title":"Neurobiol Dis"},{"key":"253_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6997(25)00441-7","volume":"45","author":"TW Stone","year":"1993","unstructured":"Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309\u2013379","journal-title":"Pharmacol Rev"},{"key":"253_CR33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148\u2013154","journal-title":"Nat Med"},{"key":"253_CR34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"253_CR35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/PL00004915","volume":"355","author":"J Urenjak","year":"1997","unstructured":"Urenjak J, Obrenovitch TP, Zilkha E (1997) Effect of probenecid on depolarizations evoked by N-methyl-d-aspartate (NMDA) in the rat striatum. Naunyn Schmiedebergs Arch Pharmacol 355:36\u201342","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"253_CR37","doi-asserted-by":"crossref","first-page":"22021","DOI":"10.1074\/jbc.M603503200","volume":"281","author":"J Wang","year":"2006","unstructured":"Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021\u201322028","journal-title":"J Biol Chem"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0253-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0253-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0253-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T21:09:12Z","timestamp":1739308152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0253-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,24]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0253-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"type":"print","value":"0300-9564"},{"type":"electronic","value":"1435-1463"}],"subject":[],"published":{"date-parts":[[2009,6,24]]}}}